Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Yu

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Physics in Medicine and Biology|June 1, 1991
Modelling approach for separating blood time-activity curves in positron emission tomographic studiesS C Huang, J R Barrio, D C Yu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2006
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerEric J Small, Michael A Carducci, James M Burke, et al.
Cancer Research|July 17, 2001
CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicityY Chen, T DeWeese, J Dilley, et al.
Cancer Research|October 19, 2001
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapyT L DeWeese, H van der Poel, S Li, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Physics in Medicine and Biology|June 1, 1991
Modelling approach for separating blood time-activity curves in positron emission tomographic studiesS C Huang, J R Barrio, D C Yu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2006
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerEric J Small, Michael A Carducci, James M Burke, et al.
Cancer Research|July 17, 2001
CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicityY Chen, T DeWeese, J Dilley, et al.
Cancer Research|October 19, 2001
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapyT L DeWeese, H van der Poel, S Li, et al.
Pageof 5